These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15995955)

  • 1. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa.
    Tam VH; Louie A; Deziel MR; Liu W; Leary R; Drusano GL
    J Infect Dis; 2005 Aug; 192(3):420-8. PubMed ID: 15995955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mathematical modelling response of Pseudomonas aeruginosa to meropenem.
    Tam VH; Schilling AN; Poole K; Nikolaou M
    J Antimicrob Chemother; 2007 Dec; 60(6):1302-9. PubMed ID: 17913722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.
    Jumbe N; Louie A; Leary R; Liu W; Deziel MR; Tam VH; Bachhawat R; Freeman C; Kahn JB; Bush K; Dudley MN; Miller MH; Drusano GL
    J Clin Invest; 2003 Jul; 112(2):275-85. PubMed ID: 12865415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial.
    Tam VH; Louie A; Fritsche TR; Deziel M; Liu W; Brown DL; Deshpande L; Leary R; Jones RN; Drusano GL
    J Infect Dis; 2007 Jun; 195(12):1818-27. PubMed ID: 17492598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs.
    Lister PD; Wolter DJ; Wickman PA; Reisbig MD
    J Antimicrob Chemother; 2006 May; 57(5):999-1003. PubMed ID: 16513915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
    Pasquali F; Manfreda G
    Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.
    Maciá MD; Borrell N; Segura M; Gómez C; Pérez JL; Oliver A
    Antimicrob Agents Chemother; 2006 Mar; 50(3):975-83. PubMed ID: 16495260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of ciprofloxacin-induced resistant Pseudomonas aeruginosa in a dynamic kill curve system.
    Wu BM; Sabarinath SN; Rand K; Johnson J; Derendorf H
    Int J Antimicrob Agents; 2011 Jun; 37(6):519-24. PubMed ID: 21497064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa.
    Rees VE; Bulitta JB; Nation RL; Tsuji BT; Sörgel F; Landersdorfer CB
    J Antimicrob Chemother; 2015 Mar; 70(3):818-26. PubMed ID: 25381167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa.
    Tam VH; Schilling AN; Neshat S; Poole K; Melnick DA; Coyle EA
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4920-7. PubMed ID: 16304153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of short-course quinolone therapy on susceptible and resistant populations of Staphylococcus aureus.
    Drusano GL; Liu W; Brown DL; Rice LB; Louie A
    J Infect Dis; 2009 Jan; 199(2):219-26. PubMed ID: 19049435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations.
    Drusano GL; Louie A; Deziel M; Gumbo T
    Clin Infect Dis; 2006 Feb; 42(4):525-32. PubMed ID: 16421797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.
    Ellis JM; Kuti JL; Nicolau DP
    Clin Ther; 2005 Nov; 27(11):1820-30. PubMed ID: 16368453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.
    Tam VH; Schilling AN; Vo G; Kabbara S; Kwa AL; Wiederhold NP; Lewis RE
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3624-30. PubMed ID: 16127031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of several fluoroquinolones and beta-lactams in terms of their capability to restrict the selection of fluoroquinolone-resistant Salmonella: in vitro models.
    Cebríán L; Rodríguez JC; Escribiano I; Royo SG
    APMIS; 2007 Dec; 115(12):1376-82. PubMed ID: 18184408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance.
    Tam VH; Louie A; Deziel MR; Liu W; Drusano GL
    Antimicrob Agents Chemother; 2007 Feb; 51(2):744-7. PubMed ID: 17116679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S38-45; discussion S64-73. PubMed ID: 16813981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; James J; Derkatch S; Laing N; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2006 Jul; 58(1):112-6. PubMed ID: 16644764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Low-level resistance to fluoroquinolones conferred by efflux overproduction in Pseudomonas aeruginosa: clinical significance and routine detection].
    Hocquet D; Patry I; Dupont P; Bize M; Jeannot K; Chavanet P; Plésiat P
    Pathol Biol (Paris); 2005; 53(8-9):495-9. PubMed ID: 16203109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.